Efficacy of dual HER2 blockade in neoadjuvant HER2-positive breast cancer: a meta-analysis of RCTs
Abstract Introduction HER2-positive breast cancer is an aggressive subtype that benefits from targeted therapies. According to the Chinese Society of Clinical Oncology (CSCO) guidelines and the National Comprehensive Cancer Network (NCCN), the combination of trastuzumab (H) with pertuzumab (P) and n...
Zapisane w:
| Główni autorzy: | , , , |
|---|---|
| Format: | Artigo |
| Język: | Inglês |
| Wydane: |
BMC
2026-01-01
|
| Seria: | Systematic Reviews |
| Hasła przedmiotowe: | |
| Dostęp online: | https://doi.org/10.1186/s13643-025-03058-w |
| Etykiety: |
Nie ma etykietki, Dołącz pierwszą etykiete!
|